|
Comparative study of rosiglitazone versus sulfonylurea as add-on therapy: economic analysis of type 2 diabetes mellitus |
Ma L, Wu N, Russo PA, Harrow BS, Menditto LA, Arondekar B |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Ma L, Wu N, Russo PA, Harrow BS, Menditto LA, Arondekar B. Comparative study of rosiglitazone versus sulfonylurea as add-on therapy: economic analysis of type 2 diabetes mellitus. American Journal of Pharmacy Benefits 2012; 4(1): e1-e7 Indexing Status Subject indexing assigned by CRD MeSH Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Sulfonylurea Compounds; Thiazolidinediones AccessionNumber 22012018470 Date bibliographic record published 09/01/2013 |
|
|
|